Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Net Income (2016 - 2025)

Historic Net Income for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $338.7 million.

  • United Therapeutics' Net Income rose 957.62% to $338.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1447.48%. This contributed to the annual value of $1.2 billion for FY2024, which is 2135.46% up from last year.
  • Per United Therapeutics' latest filing, its Net Income stood at $338.7 million for Q3 2025, which was up 957.62% from $309.5 million recorded in Q2 2025.
  • United Therapeutics' Net Income's 5-year high stood at $338.7 million during Q3 2025, with a 5-year trough of $28.3 million in Q1 2021.
  • For the 5-year period, United Therapeutics' Net Income averaged around $229.1 million, with its median value being $240.9 million (2023).
  • As far as peak fluctuations go, United Therapeutics' Net Income plummeted by 7944.81% in 2021, and later skyrocketed by 74770.32% in 2022.
  • United Therapeutics' Net Income (Quarter) stood at $112.2 million in 2021, then grew by 17.74% to $132.1 million in 2022, then soared by 64.35% to $217.1 million in 2023, then soared by 38.78% to $301.3 million in 2024, then increased by 12.41% to $338.7 million in 2025.
  • Its Net Income was $338.7 million in Q3 2025, compared to $309.5 million in Q2 2025 and $322.2 million in Q1 2025.